Paris, May 10, 2022 - After completing a first closing in March 2022 at €160 million, the Kurma Growth Opportunities fund managed by Kurma Partners announces a third equity investment in Germitec as part of the raising of 11 M€ communicated today - press release attached.

Thanks to this significant round of financing, Germitec, intends to expand the worldwide business of its specialized high-level UV-C disinfection systems for ultrasound probes.

The quality of the UV-C technology (fast, efficient and non-chemical) developed by Clément Deshays, founder of Germitec, and his initial team is already recognized by many healthcare professionals in their daily practice as well as by the main manufacturers of ultrasound probes.

With the support of its historical shareholders and new ones, the management now led by Vincent Gardès aims to convert this technological leadership into international commercial success, in particular by targeting the American market as soon as the FDA gives the green light, and thus actively contribute on a larger scale to the protection of patients against nosocomial infections.

This investment perfectly reflects the strategy of the new Kurma Growth Opportunities Fund. Based on the legacy of Kurma Partners and the strategy of its earlier-stage funds focused on technology inception and company creation, this fund aims to support innovative companies from biotech to healthtech in their transformation from R&D stage into international commercial leaders in their respective market. This third investment comes just a few months after investing into Amolyt Pharma and DNA Script, responding to the growing need for growth capital investments by European healthcare players, and demonstrating the role of Kurma to accelerate this European ecosystem.